Member Info for dafad

Dr. Ezekiel J. Emanuel
MD, Ph.D.
Ezekiel J. Emanuel is the Vice Provost for Global Initiatives, the Diane v.S. Levy and Robert M. Levy University Professor, and Co-Director of the Healthcare Transformation Institute at the University of Pennsylvania. He is also the Special Advisory to the Director General of the World Health Organization. He is on leave for 2019-2020 from being the Chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania

https://www.youtube.com/watch?v=D38dX0hXk_Q

The President holds a news conference at 5pm

This guy is pretty switched on,very interesting interview especia;;y at 9 min 50
well worth a listen

https://www.youtube.com/watch?v=7h0aVSKRmfo

Your username says it all

So from this article can we assume that Matt H was talking about us last week,gov't funding coming our way??
Govt orders would be even better

Analysis, Citing Poor Understanding Among Staff
September 11, 2020 Gary Bigger
The Food and Drug Administration is giving itself a failing grade for its use of coronavirus data.

The agency says only a small number of staff can properly interpret the data for COVID-19. The FDA was forced to turn to the private sector in a partnership to help determine the effectiveness of various COVID-19 treatments.

Principal Deputy Commissioner Dr. Amy Abernethy scored herself at just 20% when it comes to understanding COVID-19 data.

BREAKING: The NHS test and trace QR code system will be launched on Thursday 24 September in England and Wales, the Health Secretary Matt Han**** has announced.

Integumen announces that it has today sent a Notice of Annual General Meeting ("AGM") to shareholder convening a meeting for midday on 24 September 2020.

Well if the US gov are talking to SNG I think they need to announce a deal pronto,listening to the news confrence,Trump is
under immense pressure to announce a vaccine or theraputic

Will be doing a News Conference live from the White House at 3:00 P.M. Eastern.

Be a nice suprise if GB had to cut short his holiday,roll on next week.Gla

timbo0039 Sep '20 - 07:26 - 13464 of 13465
0 0 0
It has been hiding in plain sight for all to see since last Thursday (in fact there appears to be two of them)

https://www.ipo.gov.uk/p-pj?startYear=2019&startMonth=September&startDay=25th+-+6801&endYear=2020&endMonth=September&endDay=9th+-+6851&filter=synairgen&perPage=10&sort=Publication+Date

ynairgen' or the 'Company')

Patent Update

Southampton, UK - 9 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces an update on its intellectual property (IP) for its wholly-owned inhaled interferon beta asset, SNG001.

Following the results of the interim analysis of Synairgen's exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients (announced 8 September 2020), Synairgen has submitted a patent application for the use of inhaled interferon beta to treat virus-induced exacerbations in COPD patients undergoing treatment with systemic corticosteroids (e.g. oral corticosteroids).

Prior to this in July, Synairgen also submitted a patent application for the use of inhaled interferon beta in COVID-19 patients.

The Company will update the market on the progress of these patent applications as appropriate.

Richard Marsden, CEO Synairgen, said: "We are very pleased to have generated patentable findings for our wholly-owned inhaled interferon beta candidate, SNG001, in both COPD and COVID-19 patients. Whilst recognising that the COPD trial data provide a strong rationale for assessing SNG001 in COPD patients with severe viral lung infections, our immediate priority is to progress SNG001 as a therapeutic for COVID-19. Together with our advisors we are working to protect the value of this drug for shareholders and commercial partners over the longer term."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR').

For further enquiries, please contact:

rug maker AstraZeneca pauses COVID-19 vaccine trials for ‘routine’ checks due to ‘potentially unexplained illness’ during tests
The drug giant said it is “routine action” to pause trials whenever there is an unexplained illness among participants. “In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully,” according to AstraZeneca. This comes after nine major pharma companies, including AstraZeneca, signed a petition, committing to not rush the process of developing a vaccine for COVID-19.

Next Steps for COVID-19

Synairgen is in discussions with a number of regulatory agencies worldwide to establish the regulatory route to the approval of SNG001 as a treatment for COVID-19. We are also working closely with the Company's manufacturing partners on scale-up activity and will provide a further update on these matters in due course.

Richard Marsden, CEO Synairgen, said: " COPD exacerbations are the second most common cause of unplanned hospitalisation in England, behind cardiovascular disease. These interim data from our first trial of SNG001 in COPD show that SNG001 could be a valuable novel therapeutic for exacerbating COPD patients. Overall, SNG001 has now been shown to raise the body's natural viral defences when challenged by a wide variety of respiratory viruses, indicating that it could be an important treatment in the coming virus season, where there may be coinfection with influenza and other viruses alongside COVID-19.

" Our immediate priority is to progress SNG001 as a therapeutic for COVID-19 and, as such, our COPD programme will remain paused. We are, nevertheless, pleased to provide further evidence that supports SNG001 as a potential treatment for COVID-19 through the safety, biomarker, and efficacy data generated from patients in this interim review of the COPD trial."

https://uk.advfn.com/stock-market/london/synairgen-SNG/share-news/Synairgen-plc-Positive-interim-analysis-of-SNG001/83211367

08 September 2020

Press release

Synairgen plc

('Synairgen' or the 'Company')

Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients

- SNG001 well tolerated in this older population with a significant co-morbidity (COPD)
- Strong interferon driven antiviral biomarker response
- Data support future progression of SNG001 for exacerbating COPD patients
- Positive data supportive of SNG001 COVID-19 programme
Southampton, UK - 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection.

Key findings

-- Safety
SNG001 was well tolerated during the treatment period in a study population that was elderly (mean age 66 years) and suffering from reduced respiratory function, as measured by forced expiratory volume in one second (FEV1) (59% of predicted value). The percentage of on-treatment adverse events was similar in the placebo and SNG001 treatment groups (48.1% versus 45.6%, respectively), with treatment-related adverse events being more frequent in the placebo group (25%) compared to the SNG001 group (15.8%). This safety data add to the safety database for SNG001, supporting Synairgen's interactions with regulatory agencies in respect of COVID-19, where older age and poor lung function are risk factors.

-- Antiviral activity
Over the treatment period, lung antiviral responses to viral infection were significantly enhanced in patients receiving SNG001 compared to those on placebo, as assessed by measuring increases in the gene expression of interferon beta-dependent antiviral biomarkers MX1 (p=<0.001) and OAS1 (p=<0.001) in lung (sputum) cells. Analysis of blood biomarkers is ongoing.

-- Clinical endpoints
The impact of viral infection on COPD patients in the trial was most evident on peak expiratory flow rate (PEFR), a measure of lung function, and patient-reported symptoms assessed using the Breathlessness Cough and Sputum Score (BCSS), and was particularly apparent in exacerbating patients (i.e. patients already requiring treatment with oral corticosteroids and/or antibiotics at the time of randomisation, who represented one third of patients enrolled).

Exacerbating patients who received SNG001 had significantly better lung function during the treatment period (difference in change from baseline morning PEFR between patients receiving SNG001 and placebo over days 2-15 was 25.5L/min; p=0.041). Although there was no significant difference in total BCSS in this group over the treatment period, there was a trend for the breathlessness component of the score, suggesting that patients may have recovered more rapidly if they received SNG001 rather than placebo.

Viral infections had l

if so some decent exposure

https://www.ft.com/content/743ce7a0-60eb-482d-b1f4-d4de11182fa9

how to pronounce

https://www.youtube.com/watch?v=f_nl90UDREk

https://www.youtube.com/watch?v=bR8RxE81y-w